Effects of vitamin D and/or magnesium supplementation on mood, serum levels of BDNF, inflammatory biomarkers, and SIRT1 in obese women: a study protocol for a double-blind, randomized, placebo-controlled trial.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
vitamin D | decrease | inflammation and depressive symptoms | - | - | have anti-inflammatory and anti-depressant effects | #1 |
magnesium | decrease | inflammation and depressive symptoms | - | - | have anti-inflammatory and anti-depressant effects | #2 |
Dietary intake of magnesium | decrease | body mass index | - | - | associated with reduced | #3 |
Dietary intake of magnesium | decrease | waist circumference | - | - | associated with reduced | #4 |
Dietary intake of magnesium | decrease | body fat percentage | - | - | associated with reduced | #5 |
Dietary intake of magnesium | decrease | inflammatory biomarkers | - | - | associated with reduced | #6 |
Dietary intake of magnesium | decrease | depressive symptoms | - | - | associated with reduced | #7 |
Vitamin D deficiency | increase | inflammation | - | - | has been linked to | #8 |
Vitamin D deficiency | increase | obesity | - | - | has been linked to | #9 |
Vitamin D deficiency | increase | depressive symptoms | - | - | has been linked to | #10 |
vitamin D and magnesium co-supplementation | neutral | mood | obese women | - | test the effects | #11 |
vitamin D and magnesium co-supplementation | neutral | serum level of brain-derived neurotrophic factor (BDNF) | obese women | - | test the effects | #12 |
vitamin D and magnesium co-supplementation | neutral | inflammation | obese women | - | test the effects | #13 |
vitamin D and magnesium co-supplementation | neutral | sirtuin 1 (SIRT1) | obese women | - | test the effects | #14 |
vitamin D | neutral | mood | 108 obese women | - | evaluate the individual effects | #15 |
vitamin D | neutral | serum level of BDNF | 108 obese women | - | evaluate the individual effects | #16 |
vitamin D | neutral | inflammation | 108 obese women | - | evaluate the individual effects | #17 |
vitamin D | neutral | SIRT1 | 108 obese women | - | evaluate the individual effects | #18 |
magnesium | neutral | mood | 108 obese women | - | evaluate the individual effects | #19 |
magnesium | neutral | serum level of BDNF | 108 obese women | - | evaluate the individual effects | #20 |
magnesium | neutral | inflammation | 108 obese women | - | evaluate the individual effects | #21 |
magnesium | neutral | SIRT1 | 108 obese women | - | evaluate the individual effects | #22 |
vitamin D and magnesium co-supplementation | neutral | BDNF | obese women | - | may provide a new adjuvant therapy through modulation | #23 |
vitamin D and magnesium co-supplementation | neutral | inflammation | obese women | - | may provide a new adjuvant therapy through modulation | #24 |
vitamin D and magnesium co-supplementation | neutral | SIRT1 | obese women | - | may provide a new adjuvant therapy through modulation | #25 |
BACKGROUND: Emerging evidence has shown that vitamin D and magnesium have anti-inflammatory and anti-depressant effects. Dietary intake of magnesium is associated with reduced body mass index, waist circumference, body fat percentage, as well as inflammatory biomarkers and depressive symptoms. Vitamin D deficiency has been linked to inflammation, obesity, and depressive symptoms. This study will test the effects of vitamin D and magnesium co-supplementation on mood, serum level of brain-derived neurotrophic factor (BDNF), inflammation, and sirtuin 1 (SIRT1) in obese women. METHODS: We will conduct an 8-week, double-blind, randomized, placebo-controlled clinical trial, in a factorial design, to evaluate the individual effects of vitamin D and magnesium, and co-supplementation of them, on mood, serum level of BDNF, inflammation, and SIRT1 in 108 obese women. DISCUSSION: We hypothesize that vitamin D and magnesium co-supplementation may provide a new adjuvant therapy through modulation of BDNF, inflammation, and SIRT1 in obese women. TRIAL REGISTRATION: Iranian Registry of Clinical Trials, IRCT20090822002365N23. Registered on 16 August 2019.